Semaglutide News and Research

Latest Semaglutide News and Research

Dopamine neurons play a central role in sustaining hedonic eating

A previously overlooked dopamine-producing brain circuit drives hedonic eating, or eating for pleasure, according to a new study in mice.

27 Mar 2025

Older Americans support insurance coverage for obesity medications

A large majority of older Americans feel that health insurance – including Medicare – should cover anti-obesity medications, according to a new University of Michigan study.

27 Mar 2025

Unveiling leptin signaling in the DMH for metabolic effects

Scientists at Pennington Biomedical Research Center have gained greater clarity in the brain regions and neurons that control metabolism, body temperature and energy use.

27 Mar 2025

Common sugar substitute increases activity in the brain's hypothalamus

Compared to sugar, consuming sucralose-a widely used sugar substitute-increases activity in the hypothalamus, a brain region that regulates appetite and body weight, according to a new USC study.

26 Mar 2025

Flavonoids help regulate gut hormones and show promise in managing type 2 diabetes

Flavonoids show promise in treating type 2 diabetes mellitus by targeting the enteroendocrine system and regulating key gut hormones. They enhance insulin sensitivity, reduce oxidative stress, and influence appetite, glucose uptake, and hormone secretion.

26 Mar 2025

Discovery provides crucial molecular targets for future obesity treatments

The pleasure we get from eating junk food - the dopamine rush from crunching down on salty, greasy French fries and a luscious burger - is often blamed as the cause of overeating and rising obesity rates in our society.

26 Mar 2025

US Patent Office grants Closed Loop Medicine key patents for cardiometabolic capabilities in GLP-1 and Direct Oral Anti-Coagulants (DOAC) therapies

Closed Loop Medicine Ltd., a leader in AI-enabled precision medicines, today announced the expansion of its US patent portfolio. Strengthening its cardiometabolic treatment portfolio, the Company now has patents covering advancements in GLP-1 therapies for obesity and diabetes, and direct oral anticoagulants (DOACs) for cardiovascular health.

25 Mar 2025

Healthcare groups urge FDA to act on compounding regulations after GLP-1 medicine shortages

Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) sent a letter to the U.S. Food & Drug Administration (FDA), along with more than 20 leading organizations and providers across the healthcare continuum, urging the agency to enforce federal regulations around compounding following the recent resolution of GLP-1 medicine shortages.

22 Mar 2025

Exploring the therapeutic potential of flavonoids in type 2 diabetes

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily characterized by insulin resistance, β-cell dysfunction, and impaired glucose homeostasis.

20 Mar 2025

Early use of anti-obesity medication doubles weight loss

Adding an anti-obesity medication just one month after behavioral therapy begins-rather than waiting the currently recommended six months-can more than double weight loss for patients who struggle initially with lifestyle changes alone, according to new research published in Nature Medicine from a team at the Perelman School of Medicine at the University of Pennsylvania.

18 Mar 2025

Biomanufacturing platform offers a sustainable alternative to synthesizing peptide-based pharmaceuticals

To tackle the inequity in medication access, a societal issue especially in developing nations, a team of undergraduate student-researchers at the University of Ottawa has developed a new biomanufacturing platform called Phytogene.

18 Mar 2025

Keto controversy? Experts say it’s here to stay

Low-carb and ketogenic diets offer sustainable solutions for chronic disease, enhancing metabolic health and supporting weight loss through dietary changes.

18 Mar 2025

Novel cyclic peptide antagonist can be a promising therapeutic approach for MASH

The farnesoid X receptor (FXR) is a bile acid nuclear receptor that plays a crucial role in regulating bile acid and sterol metabolism.

14 Mar 2025

New insights into screening and treatment for diabetic retinal disease

Diabetes affects more than 1 in 10 adults worldwide and has been accompanied by an increase in vision-threatening diabetic retinal disease.

12 Mar 2025

Tirzepatide helps people without diabetes lose 13% body weight in real-world study

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at least six months lost an average of 12.9% of their body weight. The study highlights Tirzepatide’s potential as an effective off-label obesity treatment before its formal FDA approval for weight loss.

11 Mar 2025

Integrated anti-aging strategy could reduce neurodegeneration

Aging significantly impacts neurodegeneration, increasing risks for diseases like Alzheimer's. Research focuses on therapies to enhance cognitive function.

11 Mar 2025

GLP-1 drugs may cut risk of leukemia and lymphoma in type 2 diabetes patients

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 diabetes patients, especially compared to insulin. The study also highlights GLP-1RAs’ potential as a cancer-protective treatment, independent of glucose control.

9 Mar 2025

Semaglutide News and Research

Latest Semaglutide News and Research

Dopamine neurons play a central role in sustaining hedonic eating

Older Americans support insurance coverage for obesity medications

Unveiling leptin signaling in the DMH for metabolic effects

Common sugar substitute increases activity in the brain's hypothalamus

Flavonoids help regulate gut hormones and show promise in managing type 2 diabetes

Discovery provides crucial molecular targets for future obesity treatments

US Patent Office grants Closed Loop Medicine key patents for cardiometabolic capabilities in GLP-1 and Direct Oral Anti-Coagulants (DOAC) therapies

Healthcare groups urge FDA to act on compounding regulations after GLP-1 medicine shortages

Exploring the therapeutic potential of flavonoids in type 2 diabetes

Early use of anti-obesity medication doubles weight loss

Biomanufacturing platform offers a sustainable alternative to synthesizing peptide-based pharmaceuticals

Keto controversy? Experts say it’s here to stay

Novel cyclic peptide antagonist can be a promising therapeutic approach for MASH

New insights into screening and treatment for diabetic retinal disease

Tirzepatide helps people without diabetes lose 13% body weight in real-world study

Integrated anti-aging strategy could reduce neurodegeneration

GLP-1 drugs may cut risk of leukemia and lymphoma in type 2 diabetes patients

Naturally occurring molecule suppresses appetite and promotes weight loss

Study shows benefits of GLP-1 drugs for kidney transplant recipients with type 2 diabetes

Surgery first strategy could lead to better weight loss outcomes

Pharmaceutical Manufacturing - Industry Focus eBook eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Semaglutide News and Research

Latest Semaglutide News and Research

Pharmaceutical Manufacturing - Industry Focus eBook eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in